Fate Therapeutics, Inc. (FATE)

In the past six months, Fate Therapeutics' stock has experienced several events and fluctuations. The 52-week high was $1.94, and the 52-week low was $0.66. As of February 6, 2026, the closing price was $1.14. Key events impacting the stock include financial results, participation in investor conferences, leadership changes, and presentations of clinical data. Analyst consensus for FATE stock is generally "Hold," with an average twelve-month stock price forecast of $3.92.

The demand for Fate Therapeutics' products and services is not subject to traditional seasonal fluctuations. Demand is primarily driven by disease prevalence, clinical trial success, regulatory approvals, and market adoption upon commercialization.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and autoimmune disorders. The company utilizes a proprietary induced pluripotent stem cell (iPSC) platform to create and engineer human iPSCs, generating clonal master iPSC lines for mass production of off-the-shelf cellular immunotherapies. The company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates such as FT819 for lupus, FT522 for B-cell Lymphoma and autoimmunity, FT576 to treat multiple myeloma, FT825 for solid tumors, FT836 for solid tumors, and FT839.

Fate Therapeutics is headquartered in San Diego, California, United States. The company's development and commercialization efforts extend internationally, with authorization received from UK and EU authorities to activate ex-US clinical trial sites for FT819.

Fate Therapeutics maintains a generally positive brand reputation, driven by its innovative approach to cellular immunotherapies and promising clinical trial results. Positive clinical data for FT819, commitment to innovation, and strategic leadership growth contribute to its reputation. Potential risks include clinical efficacy, safety concerns, partnership issues, and regulatory reactions.

Fate Therapeutics, Inc. has significant institutional ownership, with 247 institutional owners and shareholders holding 97.54% of the stock. Major institutional owners include Redmile Group, LLC, BlackRock, Inc., The Vanguard Group, Inc., Wilshire Advisors LLC, and Johnson & Johnson Innovation - JJDC, Inc. Only 5.51% of the stock is held by insiders.